Oramed Pharmaceuticals Inc. develops an orally ingestible capsule for the delivery of protein-based therapies with focus on treatment of diabetes. The company advances two independent clinical programs: ORMD-0801 – an oral insulin product, and ORMD-0901 – an oral GLP-1 receptor agonist product, both targeted at the immense type 2 diabetes market. In addition, Oramed is developing a combination product of ORMD-0801+0901 and has out-licensed a different oral protein delivery technology to a 3rd party for development of an osteoporosis treatment.

For a copy of the report, fill out your details below. The link to the document will be sent to you when you click “Get the link”